Title
Author
DOI
Article Type
Special Issue
Volume
Issue
The ovarian cancers in geriatric population: the validity of inflammatory markers, malignancy risk indices 1, 2, 3, 4, and CA-125 levels in malignancy discrimination of adnexal masses
1Haydarpaşa Numune Training and Research Hospital, Gynecology and Obstetrics Clinic, Istanbul, Turkey
*Corresponding Author(s): F. Vural E-mail: fisunvural@yahoo.com.tr
Purpose: To investigate the predictive value of the Risk of Malignancy Index (RMI), CA-125, and inflammatory markers in discriminating ovarian cancers (OCs). Materials and Methods: The postmenopausal (PM) women (n = 139) with adnexal masses who underwent surgery were included. The predictive value of CA-125, RMI (1, 2, 3, and 4) and inflammatory markers [neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR)] were calculated in geriatric (G) and non-geriatric women. Results: OCs had significantly increased NLR and PLR. RMI models were highly reliable in PM (Kappa: 0.642-0.715; AUC: 0.907-0.934). CA-125 measurement alone had good accuracy and moderate reliability in PM (kappa: 0.507-0.587), excellent accuracy and moderate reliability in G, NLR, and PLR predicting OCs, showed fair agreement in the PM, while PLR had a moderate agreement with G. Conclusion: RMI algorithms were the best models for malignancy prediction. However, the rise of PLR and CA-125 levels in a G population may be used as referring adnexal masses to gynecologic oncologists.
Ovarian cancers; Risk of malignancy risk index; Adnexal masses; CA-125; cancer screening; Neutrophil lymphocyte ratio; Platelet lymphocyte ratio; Geriatric; Menopause.
F. Vural,N. Aka,S. Ertaş,G. Köse,E.C. Tüfekçi. The ovarian cancers in geriatric population: the validity of inflammatory markers, malignancy risk indices 1, 2, 3, 4, and CA-125 levels in malignancy discrimination of adnexal masses. European Journal of Gynaecological Oncology. 2016. 37(6);846-851.
[1] United Nations, Department of Economic and Social Affairs, Population
Division.: “World Population Ageing 2013”. ST/ESA/
SER.A/348. New York: United Nations Publication, 2013.
[2] Trillsch F., Woelber L., Eulenburg C., Braicu I., Lambrechts
S., Chekerov R., et al.: “Treatment reality in elderly patients with advanced
ovarian cancer: a prospective analysis of the OVCADconsortium”.
J. Ovarian Res., 2013, 6, 42.
[3] Su Z, Graybill WS, Zhu Y.: “Detection and monitoring of ovarian
cancer”. Clin. Chim. Acta, 2013, 415, 341.
[4] Jacobs I., Bast R.C. Jr.: “ The CA-125 tumor-associated antigen: a review
of the literature”. Hum. Reprod., 1989, 4, 1.
[5] Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., Grudzinskas
J.G.: “A risk of malignancy incorporating CA-125, ultrasound and
menopausal status fort he accurate preoperative diagnosis of ovarian
cancer”. Br. J. Obstet. Gynecol., 1990, 97, 922.
[6] Tingulstad S., Hagen B., Skjeldestad F.E., Onsrud M., Kiserud T.,
Halvorsen T., et al.: “Evaluation of risk of malignancy index based
on serum CA-125, ultrasound findings and menopausal status in the
preoperative diagnosis of pelvic masses”. Br. J. Obstet. Gynecol.,
1996, 102, 826.
[7] Tingulstad S., Hagen B., Skjeldestad F.E., Halvorsen T., Nustad K.,
Onsrud M.: “The risk of malignancy index to evaluate potential ovarian
cancers in local hospitals”. Obstet. Gynecol., 1999, 93, 448.
[8] Yamamoto Y., Yamada R., Oguri H., Maeda N., Fukaya T.: “ Comparison
of four malignancy risk indices in the preoperative evaluation
of patients with pelvic masses”. Eur. J. Obstet. Gynecol. Reprod.
Biol., 2009, 144, 163.
[9] Terzic M., Dotlic J., Likic I., Brndusic N., Pilic I., Ladjevic N., et
al.: “Risk of malignancy index validity assessment in premenopausal
and postmenopausal women with adnexal tumors”. Taiwan J. Obstet.
Gynecol., 2013, 52, 253.
[10] Sayasneh A., Wynants L., Preisler J., Kaijser J., Jonhsın S., Stalder C.,
et al.: “Multicentre external validation of IOTA prediction models and
RMI by operators with varied training”. Br. J. Cancer, 2013, 108, 2448.
[11] Kaijser J., Sayasneh A., Van Hoorde K.,Ghaem-Maghami S., Bourne
T., Timmerman D., Van Calster B.: “Presurgical diagnosis of adnexal
tumors using mathematical models and scoring systems: a systematic
review and meta-analysis”. Hum. Reprod. Update, 2014, 20, 449.
[12] Geomini P., Kruitwagen R., Bremer G.L., Cnossen J., Mol B.W.:
“The accuracy of risk scores in predicting ovarian malignancy: a systematic
review”. Obstet. Gynecol., 2009, 113, 384.
[13] Donskov F.: “Immunomonitoring and prognostic relevance of neutrophils
in clinical trials”. Semin. Cancer Biol., 2013, 23, 200.
[14] Balkwill F., Mantovani A.: “Inflammation and cancer: back to Virchow?
” Lancet, 2001, 357, 539.
[15] Coussens L.M., Werb Z.: “Inflammation and cancer”. Nature, 2002,
420, 860.
[16] Salazar-Onfray F., Lopez M.N., Mendoza-Naranjo A.: “Paradoxical
effects of cytokines in tumor immune surveillance and tumor escape”.
Cytokine Growth Factor Rev., 2007, 18, 171–182.
[17] Stone R.L., Nick A.M., McNeish I.A., Balkwill F., Han H.D., Bottsford-
Miller J., et al.: “Paraneoplastic thrombocytosis in ovarian cancer”.
N. Engl. J. Med., 2012, 366, 610.
[18] Krenn-Pilko S., Langsenlehner U., Thurner E.M., Stojakovic
T., Pichler M., Gerger A., et al.: “The elevated preoperative plateletto-
lymphocyte ratio predicts poor prognosis in breast cancer patients”.
Br. J. Cancer, 2014, 110, 2524.
[19] Templeton A.J., McNamara M.G., Šeruga B., Vera-Badillo F.E.,
Aneja P., Ocaña A., et al.: “Prognostic role of neutrophil-tolymphocyte
ratio in solid tumors: a systematic review and metaanalysis”.
J. Natl. Cancer Inst., 2014, 106, dju124.
[20] Templeton A.J., Ace O., McNamara M.G., Al-Mubarak M., Vera-
Badillo F.E., Hermanns T., et al.: “Prognostic role of platelet to
lymphocyte ratio in solid tumors: a systematic review and metaanalysis”.
Cancer Epidemiol. Biomarkers Prev., 2014, 23, 1204.
[21] Cho H., Hur H.W., Kim S.W., Kim S.H., Kim J.H., Kim Y.T., Lee K.:
“Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial
ovarian cancer and predicts survival after treatment”. Cancer Immunol
Immunother., 2009, 58, 15.
[22] Thavaramara T., Phaloprakarn C., Tangjitgamol S., Manusirivithaya
S.: “Role of neutrophil to lymphocyte ratio as a prognostic indicator
for epithelial ovarian cancer”. J. Med. Assoc. Thai, 2011, 94, 871.
[23] Yildirim M., Demir Cendek B., Filiz Avsar A.: “Differentiation between
benign and malignant ovarian masses in the preoperative period
using neutrophil-to-lymphocyte and platelet-tolymphocyte
ratios”. Mol. Clin. Oncol., 2015, 3, 317.
[24] Asher V., Lee J., Innamaa A., Bali A.: “Preoperative platelet lymphocyte
ratio as an independent prognostic marker in ovarian cancer”.
Clin. Transl. Oncol., 2011, 13, 499.
[25] Raungkaewmanee S., Tangjitgamol S., Manusirivithaya S., Srijaipracharoen
S., Thavaramara T.: “Platelet to lymphocyte ratio as a
prognostic factor for epithelial ovarian cancer”. J. Gynecol.
Oncol., 2012, 23, 265.
[26] Kokcu A., Kurtoglu E., Celik H., Tosun M., Malatyalıoglu E.,
Ozdemir A.Z.: “ May the platelet to lymphocyte ratio be a prognostic
factor for epithelial ovarian cancer?” Asian Pac. J. Cancer Prev.,
2014, 15, 9781.
[27] American College of Obstetricians and Gynecologists.: “ACOG
Committee Opinion: number 280, December 2002. The role of the
generalist obstetrician-gynecologist in the early detection of ovarian
cancer”. Obstet. Gynecol., 2002, 100, 14, 13.
[28] Rufford B.D., Jacobs I.J. : “Green-top Guideline No. 34. Ovarian cysts
in postmenopausal women”. London, UK: Royal College of Obstetricians and Gynaecologists, 2003. Available at: http:// www.rcog.org.uk/files/rcog-corp/GTG3411022011.pdf
[29] Suh D.H., Kim H.S., Chung H.H., Kim J.W., Park N.H., Song Y.S., Kang S.B.: “Preoperative systemic inflammatory response markers in predicting lymph node metastasis in endometrioid endometrial adenocarcinoma”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2012, 162, 206.
[30] Lee Y.Y., Choi C.H., Kim H.J., Kim T.J., Lee J.W., Lee J.H., et al.: “Pretreatment neutrophil: lymphocyte ratio as a prognostic factor in cervical carcinoma”. Anticancer Res., 2012, 32, 1555.
[31] Kwon H.C., Kim S.H., Oh S.Y., Lee S., Lee J.H., Choi H.J., et al.: “Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer”. Biomarkers, 2012, 17, 216.
[32] Smith R.A., Ghaneh P., Sutton R., Raraty M., Campbell F., Neoptolemos J.P.: “Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio”. J. Gastrointest. Surg., 2008, 12, 1422.
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.
Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.
JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Top